<SEC-DOCUMENT>0001144204-13-013138.txt : 20130306
<SEC-HEADER>0001144204-13-013138.hdr.sgml : 20130306
<ACCEPTANCE-DATETIME>20130306120842
ACCESSION NUMBER:		0001144204-13-013138
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20130306
FILED AS OF DATE:		20130306
DATE AS OF CHANGE:		20130306

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		13668711

	BUSINESS ADDRESS:	
		STREET 1:		XTL BIOPHARMACEUTICALS LTD
		STREET 2:		C/O ALSTON & BIRD LLP, 90 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		972 9 955 7080

	MAIL ADDRESS:	
		STREET 1:		85 MEDINAT HAYEHUDIM ST.
		STREET 2:		PITUACH, PO BOX 4033
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			46140
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v337281_6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the month of March, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File Number: <B>000-51310</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>&#9;<B>XTL Biopharmaceuticals Ltd.&#9;</B></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of registrant&rsquo;s name
into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>85 Medinat Hayehudim St., Herzliya </B><BR>
<B>Pituach, PO Box 4033,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Herzliya
46140, Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;(Address of
principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F <FONT STYLE="font-family: Wingdings">&#120;
</FONT>&#9;Form 40-F&#9;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes <FONT STYLE="font-family: Wingdings">&#168;</FONT>&#9;No <FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): 82-<U> N/A </U>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Incorporation by Reference: This Form
6-K of XTL Biopharmaceuticals Ltd. dated March 6, 2013 is hereby incorporated by reference into the registration statements on
Form F-3 (File No. 333-141529, File No. 333-147024 and File No. 333-153055) filed by XTL Biopharmaceuticals Ltd. with the Securities
and Exchange Commission on March 23, 2007, October 30, 2007 and August 15, 2008, respectively, and the registration statements
on Form S-8 (File No. 333-148085, File No. 333-148754 and File No. 333-154795) filed by XTL Biopharmaceuticals Ltd. with the Securities
and Exchange Commission on December 14, 2007, January 18, 2008, and October 28, 2008, respectively.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>XTL Biopharmaceuticals &ndash; Immediate
Report</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">Below&nbsp;is
an English translation (from Hebrew) of an immediate report by XTL Biopharmaceuticals Ltd. as published on the Tel-Aviv Stock Exchange
Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 41.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">Herzliya, Israel
&ndash; March 6, 2013 &ndash; </FONT>XTL Biopharmaceuticals Ltd. (the &ldquo;<B>Company</B>&rdquo;) announced today that negotiations
with Kitov Pharmaceuticals Ltd. (&ldquo;Kitov&rdquo;) (previously discussed in the Company&rsquo;s December 13, 2012 announcement)
did not materialize into a definitive agreement. As such, on March 5, 2013 the Company and Kitov mutually agreed to cease such
negotiations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About XTL Biopharmaceuticals Ltd. (&ldquo;XTL&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">XTL
Biopharmaceuticals Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical
products for the treatment of clinical unmet needs. XTL is focused on late stage clinical development of drugs for the treatment
of multiple myeloma, schizophrenia, and hepatitis C. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">XTL&rsquo;s
lead drug candidate, rHuEPO, for the treatment of multiple myeloma blood cancer, was granted an orphan drug designation from the
FDA. rHuEPO has been approved for marketing by the FDA and has for many years been sold for billions of dollars across the world
for the treatment of severe anemia. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="color: black; background-color: white">XTL
holds more than 31% in Proteologics Ltd. (TASE: PRTL), a drug discovery company, and controls InterCure Ltd. (TASE: INCR), a company
which has disrupted the $42 billion hypertension industry with the world's first FDA-cleared, OTC blood pressure treatment device,
RESPeRATE&reg; </FONT>(<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>www.resperate.com</U>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">XTL
is a public company traded on the Tel Aviv Stock Exchange (TASE: XTL) and its ADRs are quoted in the US on the Pink Sheets (OTC:
XTLBY). XTL shares are included in the following indices: Tel-Aviv MidCap-50, Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Bluetech-50.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investor Relations, XTL Biopharmaceuticals
Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel: +972 9 955 7080, Email: i<U>r@xtlbio.com</U>,
<U>www.xtlbio.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cautionary Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of the statements included in this
Form 6-K may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the
protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>XTL BIOPHARMACEUTICALS LTD.</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: March 6, 2013</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 46%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ David Grossman</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:&#9;David
    Grossman<BR>Title:&#9;Chief Executive Officer</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"``[`(L#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]X]0U/P_I
M5T8+JXT:UF`R8Y9(T;'K@\U\-?\`!<C_`(*A7_\`P3N^`_AVZ^'^FZ'JGB?Q
ME?/9V=[/"D]I8JB[F8@<,W8*:\W_`.#DK_@GGJWQK^#$/QC\"S:M!XJ\"P%=
M4MK*X=/[0L.K':IY9.N?05^;?_!(?QMX'_:GUF]_9M^-]U?ZAX/\=3?VAX9U
M-[LK<Z)JJKC]W(V2!(OR[>A)K[7(\AP]3#K,IOVD8/WX6UM]^O?S1\SF>:UH
M5G@XKE<OAE?3^NA^C'_!!G_@L?XN_;R\;>*O`OQ4TW07UK0K%=3MM8L;)+6&
M2'=M*2*/E4CJ#WK]-+;7?#=[.D,-YH4TLGW426)F;Z`&OY__`/@K%X0^&O\`
MP29^'-Q\`?@M?:E)XR\<".^\:^()[K=>0V:',5H&'^K!;#$#J#7M'_!MK_P3
MLU[Q-I6I?'SQC<:U-";6?3_!]E=W4A21BI5[DJ3@C^%?IFM<XR7"5*$LUI/V
M5.7PQMJ_/?1-_AJ9Y?F=>%58&:YYKXG?;_/_`#T/V7;Q%X81RK7V@JRG!'G1
M<'\Z3_A)/"^/^0AH'_?^'_&OYT_'G_!"S]L36OB#XAOK;2;PVM]JES<PG^W'
M&Y'E9E.,\<$5\F?M-_"+XF_L?_%2\\%^/-2UC3/$%C$L\T,>IR2*J,,@@YK3
M"<&X;$ODHXN,I6O9*[_,C$<25Z"YJF':5[7O_P``_K?_`.$D\+X_Y"&@?]_X
M?\:#XD\+_P#00\/_`/?^'_&OYF_A+_P1M_:P^.7PTT;Q=X;LKZ[T'Q!;B[LI
MGUMU:2,\`D9XZ5XK^UK^SC\7?V)/B##X3^(UYJVDZW>68O88HM4DE5HB2`V<
M^H-51X+PU:K[&EBXREV2UTWZ]"*O$U>G#VE3#M+O?O\`(_K>L;73=2MUFMX[
M&XA<?*\2HRGZ$<5,VCV>W_CUMO\`OTO^%?(G_!!"[GO_`/@E5\*YKBXGNIFL
MY"TDTA=V_>MU)YK[%KX?&8?V%>=!N_*VK^A]3A:WM:4:MK<R3^\S&_LB.]6W
M;^S5N&Z1'8)#^'6K7]C6?_/K;?\`?I?\*_-CX[:E=1_\%NO"<*W=TL#?9\Q"
M4B,]?X>E?I3<:I;6<FR:X@B8]%>0*37JYQDCP$,//FYO;4U/;:[>GGL>#P_Q
M$LRJ8J#AR^QJ.GO>]NNRMZ#?[&L_^?6V_P"_2_X54G.D6MVMO+_9D4[_`'8W
MV*[?AUK25]RA@=P(R".<U\E?M(?L">*/C-^VSX7^)FG^*H].T?0S;&;3RS!I
M?*)+=..<UQY;A</7JN&)J^S2BVG9N[6RT[]^AWYQCL5A:,:F#H^UDY)-)VLG
MO+7MV/JX:-9X_P"/6V_[]+_A1_8UG_SZVW_?I?\`"K`;BJTVJVMO+Y<EU;I)
MTVM(`WY9KSE=GJN26XO]C6?_`#ZVW_?I?\*\F^)D:VWC>^2-5C1?+PJC`'[M
M>U>P(VY>.G8^M>0_%+_D>[[_`+9_^BUH&>L:II=OK>FW%G>0QW-K=Q-#-%(N
MY948$,I'<$$BOYC_`/@LA^P+JW_!,K]MJ/6/#/VBS\)Z]>C7?"][%P+&=7WM
M!GL4;D#^[BOZ;]4U6WT/3KF\O)H[:TLXFFFED.U(D499B>P`!-?S-_\`!9K_
M`(*"ZK_P4X_;0MO#OA/SKWP?X=O_`.Q/#-I&.=2N6?8T^/\`:8X!_NXK[K@/
MZQ]=ER?P[>_?:W3Y_I<^5XL]E]67-\=_=MOYG&?L,_LP^-_^"Q_[?2Q>)-4N
M=2:\D35/%VKRM\RVJ8&T>[XV#%?U"_#CX>Z/\*?`>D^&]!LH=/T?0[5+.TMX
MU"K'&@P/QXR3W)K^5[]E/]H'X@?\$A?VZ[74M5L;S2M4\.W"V7B;1I/^7FTD
MP7!'<A3N4^M?U*?!SXN:'\>/A;H7C#PU?1:AHGB"SCO+6:-MP*L,X/N#D$=B
M#71Q]&M[6DXV]C;W;;?UV\C'A)T_9S4OXE_>ON=17\RG_!R3_P`I0/&'_8,M
MO_0!7]-:G(K^93_@Y)_Y2@>,/^P9;?\`H`KG\/\`_D9/_"_S1T\5_P"Z+_$O
MU/W?_P""29S_`,$W?@]_V+\7_H35^-7_``=4G/\`P4*T'_L58O\`T8U?LK_P
M22_Y1N_!W_L7XO\`T)J_&G_@ZH_Y2$Z%_P!BK%_Z,:M.$_\`D?S_`.W_`,S#
MB#_D4Q_[=_(_5K_@@-_RBB^%/_7E)_Z-:OLBOC;_`(($'_C5#\*?^O*3_P!&
MM7V.#S][]*^3SC_?JW^*7YGT&6?[I3_PK\C\D/\`@HK\2=5^$G_!4>W\0:%9
MI?:Y9VT"V$##(>9LA>._)KUV+_@DU\5/C=II\4>-OC!JUIXJU(?:?LL!9H+0
MM\PC'(P!G''I7%_M2:/;Z]_P6K\(6UR%:+S[-RK="0217ZC;1BOTOB#B*OEN
M!R^."2C-T8MR<4W:[LE=.RW;MN?C'"_"N&S?,LSEF#E*G&O)1@I.*N]Y.S5W
MLE?8_-/]D;]J#XD?L7_M:0_!7XK:I-K6CZG*L%A?3N7:)F_U;HYY*-T(/3%;
M'[;_`,4O$WA__@J]\-=%T_Q!JUGHUY]C\^QAN"L$V6;.Y>AS7*_\%F($M?VT
MOA7<6P"WS^2-R_>.)?EJ?]MDEO\`@KI\']WWC%IV[\VKV<'A<-B:]#-'3C&5
M?#UG))*W-%6YDME??0\+,,5BL)AL1D_M92AA\514&V^;DFV^5OJD>P?\%2OV
M]_$'P8UK2?AC\.5+>-_$NP/<(NY[1'.$"#^^W//;%<%X6_X(W>/?&WAA=9\7
M?&+Q%;^++I/.:*%VDCA<\[2Q(/'L*Y&_C7Q)_P`%V5CU9?,CM+I?LHDY'R(-
MF/S-?J'CUKY;,\RJ</X+"8;+4HSJ4U4G-Q3<G+97:=DET/L<GRFEQ/C\;B\V
M<I0I5)4J<%*48Q4=Y6BU>3?5GYJ?LU?M6_$K]A;]J:W^#_Q>U.;7M`U21(=.
MU.9R[0AS^[D5SR4/0@]*^S/B@V[QS?$<@^61_P!^UKXU_P""]%C;V7C?X6ZA
M!M34O.D7<OWBH="OZU]::M/)=/:239,LEC:,Y/4L;>,FO.XMHT:^"P><0@H3
MK*2FHJR<H.W,ETOU/7X'KU\-F&.R&I-U(8>47!R=VHS5^5OK;H?"G_!RM_P5
M$_X4E\-%^!W@O4)$\6>+K??KL]OG=IM@?X,CHTG3']TU\T?\&QO_``3F7XQ_
M%VY^-WB?3W;PWX+<VWA^.>/Y;N]Q\TN#U"`\'^]7[@>*_P!FKX=^.O$$^JZW
MX(\*ZMJEU@2W5YID,TTF!@99E)XKHO!W@71?AWH4>EZ#I.G:+IL))CM;*W6"
M%">I"J`*\NEQ%##Y6\!AH<LI?%*^_?\`R/K:F3RJXY8NO*ZCLC\AO^#H3_@G
M-_PDWAC3_P!H#PGIS2:EHR+8>)XH4RT]L3B.<@=2IP"?2O,/^#9;_@I^OPX\
M9-\`?&5_(NAZZ[7/A2XG!VV]P>7MLGHK=1[FOW2U[P_8^*-(N-/U*SM=0L;I
M#'-;W$0DBE4]0RG@CZUQ.E_LF?"_0]1M;RR^'O@VSNK-Q);S0Z1!')"PZ%6"
MY!'M54>(H2RMY;BJ;E;X7?5=ON_+053)Y1QJQE"7+W7<]`7.*_F3_P"#DJ8#
M_@J%XP7;)_R#+?HA/\`K^FP#'\5<7XQ_9M^'WQ#UN34M>\$^%=:U&90DES>Z
M9#/,X'0%F4FN/AW.5EF)>(E'FT:M>V]CJS?+GC:*I)VUN>4?\$D7W?\`!-OX
M.MSC_A'XNHQ_$U?C5_P=3N#_`,%$-!7;(?\`BE8<X0G_`):-7]"N@>'+'PIH
M]OIVEV=KI^GVB>7!;6\8CBA7T51P!]*YWQQ\`/`_Q-U=-0\1^$?#>O7T:>4M
MQ?Z=%<2JG]T,RDX]JO)\\6"S!XYPO?FTOW,\QRMXG!K"J5K6U]$?S@?LJ_\`
M!P#\;OV/?@-H'PY\*Z;X;FT+PW$8;5[NS+3%2Q;YCCU)KT+_`(BFOVC@.=)\
M'_\`@`?\*_>0_L??"<?\TW\#_P#@EM__`(BC_AC[X3Y_Y)OX'_\`!+;_`/Q%
M>U4XDRBI-U)X)-O5Z]?N/-IY-F$(J$<1HC\,?@S^V?\`$W]M[XQZ)\5)=,MY
MO'UC.LMO:6$)2.5(/FP![BOU-\&_\%M/A)>^"TN/$4NJ:#K]O'MO-+EMCYBS
M#[RK^.<9Q7TUX4^`'@?P'>PW.B>$?#FDW%N28I+/3XH6C)ZX*J,5A>+/V._A
M=XX\1'5M4\#^';O4&;>\S6BAI#ZG`YKMS+BS)LRA1H8S"RC&E%1BX22?FG=6
MMVZH^3R_@O/<KQ&(Q>78N#=>;E*,XMQ79IIWYEK?HSX`^"^E^(?^"I7_``4!
ML_B/<:/=Z9\/_",D;V[SH0LBQG,:#/#,QR3CI6O^WHZQ?\%A?A8.1M^P@8'`
M^9J_23PWX4TWP=I$>GZ38V>FV,/W(+:(1QK]`.*IZK\,_#VO>(X-8OM#TN[U
M6UQY-Y+;(\T6.FUB,C'M7/#CB,<;[:%&U*%*5*$$]E)6NW;5WU9I/PYG/+_8
M3K\U>=:-:I-KXG%[)+9=$?`W_!5W]F[Q9\,?CGX?^/G@.TFO9M(>(ZG#`A9H
MC&?ED*CDJ02#7I'@/_@M]\']:\"17NN7&H:+K4<0^TZ<T!9_,`^8*>F,],U]
MDS6RW,+1R*LD<BE61ERK`]017F6M?L4_"CQ#KC:E=^`O#<MVS;F?[&HW'U(`
MQ7)1X@R_%8.EA,XHRDZ2M"<))/E_EDFFFET>Z._$<+9I@L?6QV0UH05=WG"I
M%N/-_-%IW3?5;'Y[Z):^*/\`@KU^VOIGB/\`LF\TGX:>$Y4*R3H54Q*V[`)X
M:1SZ<#%?>WQ*@6U\:7<<:[8XUB50.P$2`5ZEX:\):;X,TB/3](L+/3+&'[D%
MM"L<:_@*\P^*7_(]WW_;/_T6M>9Q#GRS&5.E1I^SHTERPC>]ENVWU;>[/7X6
MX9>51JUL14]K7K2YJD[6N^B2Z)=#V"BO-/\`A8&K_P#/Y_Y"3_"C_A8&K_\`
M/Y_Y"3_"OG3ZP]*V_6ESBO-/^%@:O_S^?^0D_P`*/^%@:O\`\_?_`)"3_"@#
MTO%%>:?\+`U?_G\_\A)_A1_PL#5_^?S_`,A)_A0!Z70#FO-/^%@:O_S^?^0D
M_P`*/^%@:O\`\_?_`)"3_"@#TO&:*\T_X6!J_P#S^?\`D)/\*/\`A8&K_P#/
MY_Y"3_"@#TNC%>:?\+`U?_G\_P#(2?X4?\+`U?\`Y_/_`"$G^%`'I=%>:?\`
M"P-7_P"?S_R$G^%'_"P-7_Y_/_(2?X4`>ET5YI_PL#5_^?S_`,A)_A1_PL#5
M_P#G\_\`(2?X4`>EUX_\4O\`D>[[_MG_`.BUK5_X6!J__/Y_Y"3_``KGM<NI
6-7U26XN&\R:3&YL8S@`#@<=!0!__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
